Last update 01 Nov 2024
Angitia Biopharmaceuticals Guangzhou Ltd.
Last update 01 Nov 2024
Overview
Basic Info
Introduction Angitia Biopharmaceuticals Guangzhou Ltd. is a biopharmaceutical company based in Guangzhou, China, specializing in the development of treatments for musculoskeletal disorders. The company was established in 2018 by Hua Zhu Ke and Muyu Li, with Hua Zhu Ke serving as the CEO. |
Tags
Skin and Musculoskeletal Diseases
Congenital Disorders
Endocrinology and Metabolic Disease
Bispecific antibody
Biological products
Antibody
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Safety, Tolerability and Efficacy of AGA2118 in Postmenopausal Women With Low Bone Mineral Density
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Lntervertebral Local Administration of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Lnterbody Fusion
一项评估AGA111在退行性椎间盘疾病患者接受椎体间融合术时单次椎体间局部给药的疗效和安全性的随机、双盲、安慰剂对照的III期研究
[Translation] A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of a single intervertebral local administration of AGA111 in patients with degenerative disc disease undergoing intervertebral fusion
100 Clinical Results associated with Angitia Biopharmaceuticals Guangzhou Ltd.
Login to view more data
Login to view more data
27 Oct 2023
License out/inADCDrug Approval
100 Deals associated with Angitia Biopharmaceuticals Guangzhou Ltd.
Login to view more data
100 Translational Medicine associated with Angitia Biopharmaceuticals Guangzhou Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 26 Nov 2024
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
3
1
IND Approval
Phase 1 Clinical
1
1
Phase 2 Clinical
Phase 3 Clinical
1
4
Other
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free